Chugai Pharmaceutical Co Ltd CHGCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $37.84
- Day Range
- $37.45–39.93
- 52-Week Range
- $34.79–68.08
- Bid/Ask
- $22.79 / $67.54
- Shares Outstanding
- 1.65B
- Market Cap
- $62.98B
- Volume/Avg
- 11,441 / 8,583
Key Statistics
- Price/Earnings (Normalized)
- 20.03
- Price/Sales
- 7.16
- Dividend Yield (Trailing)
- 2.26%
- Dividend Yield (Forward)
- 2.18%
- Dividend Payment Schedule
- Mar, Aug
- Total Yield
- 2.30%
Company Profile
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 7,872
- Website
- https://www.chugai-pharm.co.jp
Competitors
Valuation
|
Metric
|
CHGCF
|
4568
|
4502
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.03 | 18.69 | 48.22 |
Price/Book Value | 4.97 | 2.93 | 1.20 |
Price/Sales | 7.16 | 2.39 | 1.96 |
Price/Cash Flow | 18.07 | 38.02 | 10.96 |
Price/Earnings
CHGCF
4568
4502
Financial Strength
|
Metric
|
CHGCF
|
4568
|
4502
|
|---|---|---|---|
Quick Ratio | 3.43 | 1.46 | 0.54 |
Current Ratio | 4.35 | 2.42 | 1.14 |
Interest Coverage | 9,780.06 | 28.88 | 0.07 |
Quick Ratio
CHGCF
4568
4502
Profitability
|
Metric
|
CHGCF
|
4568
|
4502
|
|---|---|---|---|
Return on Assets (Normalized) | 19.65% | — | 5.53% |
Return on Equity (Normalized) | 23.42% | — | 11.34% |
Return on Invested Capital (Normalized) | 23.42% | — | 7.74% |
Return on Assets
CHGCF
4568
4502
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|&$K?G^$ | LOCK|Q>D | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|m$N??? | LOCK|>k | $617B | |||
| AbbVie Inc
ABBV
| LOCK|#>Ff#G^ | LOCK|qz | $464B | |||
| Merck & Co Inc
MRK
| LOCK|XhfxQX | LOCK|CC | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|hn^mDHl | LOCK|&k | $333B | |||
| Novartis AG ADR
NVS
| LOCK|qL>bHH$ | LOCK|>$S | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|$PMRK<>> | LOCK|bsl | $243B | |||
| Amgen Inc
AMGN
| LOCK|G<?V!J#$ | LOCK|$?Z | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|Lh>GB@? | LOCK|qq | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!$<@%! | LOCK|H$> | $165B |
United States